Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. ALAR
4. PRYMY
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. CCHGY
10. PRY:IM

Go back to Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)

Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at Stifel; Path Forward Complicated, But Still There

February 14, 2018 6:28 AM EST

Stifel lowered its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $6.00 (from $13.00) while maintaining a Buy rating following the Phase 3 IGNITE3 trial failure.

Analyst Stephen Willey commented, "The failure of the P3 IGNITE3 trial to demonstrate the non-inferiority (NI) of intravenously-administered eravacycline vs.... More